MedTrace Logo

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

NCT03546452 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-06-07

No results posted yet for this study

Summary

A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.

Conditions

  • Malignant Hydrothorax
  • NSCLC

Interventions

DIAGNOSTIC_TEST

in vitro NGS-panel

cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel

Sponsors & Collaborators

  • Sinotech Genomics Co., Ltd

    collaborator UNKNOWN

  • Amoy Diagnostics

    collaborator INDUSTRY

  • Guangzhou Burning Rock Medical Examination Institute Co., Ltd.

    collaborator INDUSTRY

  • Geneplus-Beijing Co. Ltd.

    collaborator INDUSTRY

  • Berry Genomics Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Chest Hospital

    lead OTHER

Principal Investigators

  • shun lu, Prof. · Shanghai Chest Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-18
Primary Completion
2018-09-30
Completion
2019-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03546452 on ClinicalTrials.gov